Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 Read more about Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results Read more about Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder Read more about Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder Read more about Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree Read more about Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit Read more about Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference Read more about Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA Read more about Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
Supernus Announces Second Quarter 2024 Financial Results Read more about Supernus Announces Second Quarter 2024 Financial Results
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device Read more about Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device